Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2025

Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer

TG4050

Published 19 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders

investor meetings

Published 13 June 2025
Categorized as 2025, Press release

Listen to Prof. Ottensmeier explain the TG4050 Phase 1 data

link to webcast

Published 6 June 2025
Categorized as 2025, Myvac, TG4050, Webcast, Webcast

Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

ASCO 2025 TG4050 webinar

Published 3 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccin TG4050

ASCO TG4050

Published 1 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

ASCO 2025 TG4050

Published 1 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

ASCO Abstract

Published 22 May 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

ASCO 2025 TG4050

Published 22 May 2025
Categorized as 2025, Myvac, Press release, TG4050

Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)

C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Rapid Oral Presentation

Published 22 May 2025
Categorized as 2025, Myvac, Publication, publication key en, TG4050

A randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic(R/M) HPV16-positive cervical or anogenital cancer

C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Poster

Published 22 May 2025
Categorized as -others, 2025, Publication, TG4001, TG4001

Posts pagination

Newer posts Page 1 … Page 4 … Page 6 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu